drug
(phentermine hydrochloride + topiramate) ER
Marketedupdated 3mo agoby Vivus LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6indications
investigational
Obesity
all catalysts(22)
approval · 22
Jul 17, 2012
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Nov 1, 2012
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Mar 19, 2013
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Apr 16, 2013
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Sep 24, 2013
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Oct 17, 2013
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Sep 26, 2014
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Sep 26, 2014
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Sep 26, 2014
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Jan 27, 2017
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Mar 23, 2018
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Oct 19, 2020
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Mar 31, 2021
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Mar 8, 2022
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Jun 24, 2022
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
May 9, 2023
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Jun 28, 2023
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Feb 6, 2024
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Sep 13, 2024
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Nov 19, 2024
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Jul 11, 2025
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Mar 6, 2026
approval
QSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval
(phentermine hydrochloride + topiramate) ER
→
Trials studying (phentermine hydrochloride + topiramate) ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 13, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Jun 14, 2029method-of-use (U-3399)US 85802992.8y
- Jun 14, 2029method-of-use (U-3399)US 85802992.8y
- Jun 14, 2029method-of-use (U-3399)US 85802992.8y
- Jun 14, 2029method-of-use (U-3399)US 85802992.8y
- May 15, 2029formulationUS 85802982.8y
- May 15, 2029formulationUS 85802982.8y
- May 15, 2029formulationUS 85802982.8y
- May 15, 2029formulationUS 85802982.8y
- Jun 9, 2028method-of-use (U-3398)US 88950571.8y
- Jun 9, 2028method-of-use (U-3398)US 88950571.8y
- Jun 9, 2028method-of-use (U-3398)US 88950571.8y
- Jun 9, 2028method-of-use (U-3398)US 88950571.8y
- Jun 9, 2028formulationUS 88950581.8y
- Jun 9, 2028formulationUS 88950581.8y
- Jun 9, 2028formulationUS 88950581.8y
- Jun 9, 2028formulationUS 88950581.8y
- Jun 9, 2028formulationUS 90119051.8y
- Jun 9, 2028formulationUS 90119051.8y
- Jun 9, 2028formulationUS 90119051.8y
- Jun 9, 2028formulationUS 90119051.8y
- Jun 9, 2028method-of-use (U-3398)US 90119061.8y
- Jun 9, 2028method-of-use (U-3398)US 90119061.8y
- Jun 9, 2028method-of-use (U-3398)US 90119061.8y
- Jun 9, 2028method-of-use (U-3398)US 90119061.8y
FDA exclusivities (4)
- Sep 13, 2027M-308Method (3y)1.1y
- Sep 13, 2027M-308Method (3y)1.1y
- Sep 13, 2027M-308Method (3y)1.1y
- Sep 13, 2027M-308Method (3y)1.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that